NCT04835168View on ClinicalTrials.gov

Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

January 30, 2022

Primary Completion Date

April 30, 2022

Study Completion Date

June 30, 2022

Conditions

Eosinophilic Esophagitis

Interventions

DRUG

BT-11 low

Oral

DRUG

BT-11 high

Oral

DRUG

Placebo

Oral

Sponsors

Lead Sponsor

NImmune Biopharma

All Listed Sponsors

lead

NImmune Biopharma

INDUSTRY

NCT04835168 - Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis | Biotech Hunter | Biotech Hunter